<DOC>
	<DOC>NCT01575483</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Onglyza® so that the regulatory authority can manage the marketing approval properly.</brief_summary>
	<brief_title>Korean Post-marketing Surveillance for Onglyza®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Female and male patients who are at least 18 years of age Patients with diagnosis of T2DM initiating Onglyza® treatment within the approved indications in Korea Indication which is not approved for Onglyza® in Korea Patients with contraindication for the use of Onglyza® (as clarified in Korean label)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>